Skip to content

JBIO JBIO Debt-to-assets

Debt-to-assets at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
0.1×0.0×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-0.1×
Vera Therapeutics logo
Vera TherapeuticsVERA
0.1×0.0×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
0.0×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0.0×

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

Based on the most recent quarter.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's debt-to-assets?
JBIO (JBIO) reported debt-to-assets of 0× in Q1 2026.
How has JBIO's debt-to-assets changed year-over-year?
JBIO's debt-to-assets decreased by 37.5% year-over-year, from 0× to 0×.
What is the long-term trend for JBIO's debt-to-assets?
Over 4 years (2021 to 2025), JBIO's debt-to-assets has grown at a -7.7% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.